BackEuropean Biotech Acquisition Overview

European Biotech Acquisition Other Liabilities

Track European Biotech Acquisition's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

European Biotech Acquisition Other Liabilities History

Loading

European Biotech Acquisition vs. peers: Other Liabilities Comparison

Loading

European Biotech Acquisition Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

European Biotech Acquisition (EBAC) FAQ

As of the most recent data (December 2022), EBAC shows a other liabilities of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EBAC's other liabilities is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether European Biotech Acquisition is outperforming or lagging.

Tracking EBAC's other liabilities over time shows whether European Biotech Acquisition is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other liabilities page, Stockcircle has European Biotech Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other liabilities (currently $0) with ownership activity and broader fundamentals.